

TABLE OF CONTENTS

<u>Section 1</u>	<u>Page No.</u>
1. Introduction	1
1.1. Pathophysiology	1
1.2. Therapeutics	4
1.2.1. Anti-amyloid approach	4
1.2.1.1. Targeting amyloid transport	4
1.2.1.2. Alteration of secretase enzymes	5
1.2.1.3. Targeting amyloid aggregation	5
1.2.1.4. Targeting amyloid clearance	5
1.2.1.5. Amyloid based vaccine therapy	5
1.2.2. Targeting tau protein	6
1.2.2.1. Inhibition of tau phosphorylation	6
1.2.2.2. Targeting microtubule stabilization	6
1.2.2.3. Attenuating tau oligomerization	6
1.2.2.4. Enhancing tau degradation	6
1.2.2.5. Tau based vaccination therapy	7
1.2.3. Targeting intracellular signaling cascade	7
1.2.4. Modulation of neurotransmitter levels	7
1.2.4.1. Cholinesterase inhibitors (ChEIs)	7
1.2.4.2. Modulation of GABAergic neurons	8
1.2.4.3. NMDA receptor antagonist	8
1.2.4.4. Modulation of serotonin receptor	9
1.2.4.5. Histaminergic modulators	9
1.2.5. Targeting mitochondrial dysfunction	9
1.2.6. Targeting oxidative stress	10
1.2.7. Anti-inflammatory therapy	10
1.2.8. Multi-target-directed ligands	11
2. Research Envisaged	12
3. Materials and methods	15
3.1. <i>In vitro</i> AChE and BuChE inhibition assays	15
3.2. Thioflavin T (ThT) assay for determining A β ₁₋₄₂ aggregation inhibitory effect of the test compounds	15
3.3. Congo red (CR) binding assay for determining A β ₁₋₄₂ aggregation inhibitory effect of the test compounds	16
3.4. Determination of cell viability and neuroprotection against H ₂ O ₂ insult using SH-SY5Y cells	16
3.5. 2,2-Diphenyl-1-picrylhydrazyl radical (DPPH) assay to determine free radical scavenging ability of the test compounds	17
3.6. <i>In vitro</i> blood-brain barrier permeation assay	17
3.7. Animals	18
3.8. Effect of the test compounds on AD-like phenotype using scopolamine-induced mice model	18

3.8.1. Morris water maze test to assess spatial learning ability	19
3.8.2. Effect of test compounds on neurochemical levels	19
3.9. Effects of test compounds on hippocampal neurons	20
3.9.1. Culturing of hippocampal neurons	20
3.9.2. Effect of test compounds on cell viability against A β ₁₋₄₂ toxicity	20
3.9.3. Determination of ROS scavenging ability of test compounds	20
3.9.4. Effect of test compounds on apoptotic cell death assessed by Hoechst staining	21
3.9.5. Effect of test compounds on rate of apoptosis assessed using flow cytometry	21
3.9.6. Immunocytochemistry (ICC) of hippocampal cells exposed to A β ₁₋₄₂ to evaluated caspase-3 activation	21
3.10. Effect of test compounds on A β ₁₋₄₂ -induced Alzheimer's rat model	22
3.10.1. Y maze test to assess immediate working memory	22
3.10.2. Western blot analysis	23
3.11. Acute toxicity study	23
3.12. Pharmacokinetic study	24
3.13. Statistical analysis	24
4. Results	26
4.1. Test compounds exhibited good anticholinesterase activity	26
4.2. Test compounds attenuated A β ₁₋₄₂ aggregation	26
4.3. Test compounds showed neuroprotective effect in SH-SY5Y cells	41
4.4. Test compounds showed antioxidant activity in DPPH assay	42
4.5. Test compounds showed passive <i>in vitro</i> BBB permeability	43
4.6. Test compounds (13 , 17 , 70 and 131) showed protection in scopolamine-induced AD-like phenotype in mice model	44
4.6.1. Test compounds (13 , 17 , 70 and 131) showed enhanced spatial learning ability in MWM test	44
4.6.2. Test compounds (13 , 17 , 70 and 131) showed <i>in vivo</i> anti-ChE and antioxidant activities	45
4.7. <i>In vitro</i> neuroprotective effect of test compounds (13 , 17 and 70) on primary rat hippocampal neurons	48
4.8. Antiapoptotic potential of test compounds (13 , 17 and 70)	49
4.9. Test compounds (13 , 17 and 70) attenuated <i>in vitro</i> cleaved caspase-3 activation	50
4.10. Test compounds (13 , 17 , 70 and 131) possessed ROS scavenging activity	52
4.11. Test compounds (13 , 17 , 70 and 131) attenuated apoptosis rate	52
4.12. Beneficial effects of the test compounds in A β ₁₋₄₂ -induced Alzheimer's rat model	54
4.12.1. Test compounds (13 , 17 , 70 and 131) improved "spontaneous alteration" behaviour in Y maze test	54
4.12.2. Test compounds (13 , 17 , 70 and 131) reduced A β ₁₋₄₂ , <i>p</i> -tau, cleaved caspase-3 and cleaved PARP burden	55
4.12.3. Test compounds (13 , 17 and 70) activated the canonical Wnt/ β -catenin	57

pathway	
4.13. Test compound (131) was found safe in acute toxicity study	58
4.14. Test compound (131) exhibited good Pharmacokinetic profile	59
5. Discussion	61
6. References	67

<u>Section 2</u>	<u>Page No.</u>
1. Introduction	75
1.1. Classification of 5-HT receptors	76
1.1.1. 5-HT ₁ receptor family	76
1.1.1.1. 5-HT _{1A} receptors	77
1.1.1.2. 5-HT _{1B} receptors	77
1.1.1.3. 5-HT _{1D} receptors	78
1.1.1.4. 5-HT _{1e} receptors	78
1.1.1.5. 5-HT _{1F} receptors	79
1.1.2. 5-HT ₂ receptor family	79
1.1.2.1. 5-HT _{2A} receptors	79
1.1.2.2. 5-HT _{2B} receptors	80
1.1.2.3. 5-HT _{2C} receptors	80
1.1.3. 5-HT ₃ receptors	80
1.1.4. 5-HT ₄ receptors	81
1.1.5. 5-HT ₅ receptors	82
1.1.6. 5-HT ₆ receptors	82
1.1.7. 5-HT ₇ receptors	82
1.2. Therapeutic implications of 5-HT _{2C} receptors	83
1.2.1. Obesity	83
1.2.2. Anxiety	84
1.2.3. Depression	85
1.2.4. Penile erection	86
2. Research Envisaged	87
3. Materials and methods	88
3.1. Animals	88
3.2. <i>In vitro</i> 5-HT _{2A} bioassay using isolated rat thoracic aorta strip	88
3.3. <i>In vitro</i> 5-HT _{2B} bioassay using isolated rat fundus preparation	88
3.4. <i>In vivo</i> rodent models for 5-HT _{2C} receptor agonistic activity	89
3.4.1. Despair swim test	89
3.4.2. Elevated plus maze test	89
3.4.3. Hypophagic response	89
3.4.4. Penile erection model	90
3.4.5. Estimation of monoamines in rat brains	90
3.5. Statistical analysis	91
4. Results	92
4.1. Effect of the test compounds on 5-HT _{2A} and 5-HT _{2B} receptors as assessed using	92

rat thoracic aorta and rat fundus preparations <i>in vitro</i>	
4.2. Test compounds exhibited depressogenic effects in despair swim test	95
4.3. Test compounds showed anxiogenic affects in elevated plus maze test	96
4.4. Test compounds showed hypophagic effects	97
4.5. Test compounds induced penile erection	98
4.6. Test compounds reduced DA and 5-HT levels in the rat brain	98
5. Discussion	100
6. References	103

<u>Section 3</u>	<u>Page No.</u>
1. Introduction	109
1.1. NMDA receptors	110
1.2. AMPA and kinate receptors	111
1.3. Metabotropic receptors	111
1.4. NMDAR-mediated excitotoxicity	112
1.5. Alzheimer's disease and excitotoxicity	114
2. Research Envisaged	117
3. Materials and methods	119
3.1. Cell culturing and MTT assay for determining NMDAR antagonism of test compounds	119
3.2. Thioflavin T (ThT) assay for determining A β ₁₋₄₂ aggregation inhibitory activity of the test compounds	119
3.3. Congo red (CR) binding assay for determining A β ₁₋₄₂ aggregation inhibitory activity of the test compounds	120
3.4. Effects of test compounds on hippocampal neurons	120
3.4.1. Culturing of rat hippocampal neurons	120
3.4.2. Assessment of the effect of test compounds on cell viability challenged by A β ₁₋₄₂ -induced excitotoxicity	121
3.4.3. ROS scavenging activity of test compounds	121
3.4.4. Assessment of apoptotic cell death by Hoechst staining	121
3.4.5. Estimation of the rate of apoptosis by flow cytometry	122
3.4.6. Effect of test compounds on caspase-3 activation in hippocampal cells exposed to A β ₁₋₄₂	122
3.5. <i>In vitro</i> blood-brain barrier permeation assay	123
3.6. Effect of test compounds in A β ₁₋₄₂ -induced excitotoxicity model of rat	123
3.6.1. Morris water maze test for assessing spatial learning ability	124
3.6.2. Y maze test for assessing immediate working memory	124
3.6.3. Effect of test compounds on neurochemical levels	124
3.6.3.1. Estimation of MDA and catalase levels in rat brain	124
3.6.3.2. Estimation of glutamate and glycine levels in rat brain	125
3.7. Western blot analysis	125
3.8. Molecular dynamics and relative binding affinity studies	126
3.9. Statistical analysis	127
4. Results	128

4.1. Test compounds (3 and 10) protected SH-SY5Y cells against NMDA-induced excitotoxicity	128
4.2. Test compounds (3 and 10) attenuated A β ₁₋₄₂ aggregation	128
4.3. Test compounds (3 and 10) protected primary rat hippocampal neurons against A β ₁₋₄₂ -induced excitotoxicity	134
4.4. Test compounds (3 and 10) showed ROS scavenging activity	135
4.5. Test compounds (3 and 10) attenuated <i>in vitro</i> cleaved caspase-3 activation	135
4.6. Test compounds (3 and 10) attenuated rate of apoptosis	136
4.7. Test compounds (3 and 10) attenuated caspase-3 activation <i>in vitro</i>	137
4.8. Test compounds (3 and 10) showed good passive BBB permeability	139
4.9. Test compounds showed neuroprotective effects in A β ₁₋₄₂ induced excitotoxicity rat model	140
4.9.1. Test compounds (3 and 10) enhanced learning and memory	140
4.9.2. Test compounds (3 and 10) showed <i>in vivo</i> antioxidant activity	142
4.9.3. Test compounds (3 and 10) attenuated glutamate and glycine levels	142
4.10. Test compounds (3 and 10) reduced A β ₁₋₄₂ , <i>p</i> -tau, cleaved caspase-3 and cleaved PARP burden	143
4.11. Test compounds (3 and 10) attenuated activation of tau kinases	145
4.12. Test compound (10) showed relatively higher affinity towards glycine binding site of NMDAR	146
5. Discussion	149
6. References	155

<u>Section 4</u>	<u>Page No.</u>
1. Introduction	161
1.1. Dopaminergic pathways in the CNS	161
1.1.1. Nigrostriatal pathway	161
1.1.2. Mesocorticolimbic pathway	162
1.1.3. Tuberoinfundibular pathway	162
1.2. Classification of DA receptors	162
1.3. DA receptor expression	164
1.4. Functions of DA receptors	165
1.5. Parkinson's disease	166
1.5.1. Oxidative stress in PD	166
1.5.2. Direct and indirect pathways	167
2. Research Envisaged	169
3. Materials and methods	171
3.1. Animals	171
3.2. Effects of test compounds on rat superior mesenteric artery strip	171
3.3. MTT assay to determine D ₁ receptor agonism by test compound	172
3.4. Effect of test compound in 6-OHDA-lesioned rat model of Parkinson's disease	172
3.4.1. Drug-induced rotational behaviour	173
3.4.2. Effect of test compound on neurochemical levels	173

3.4.2.1. Reduced glutathione (GSH)	173
3.4.2.2. Lipid peroxidation potential (LPO)	173
3.4.2.3. Superoxide dismutase (SOD)	174
3.4.2.4. Catalase activity	174
3.4.2.5. Estimation of DA level using HPLC technique	174
3.4.3. Immunohistochemical analysis of substantia nigra neurons to determine cleaved caspase-3 and tyrosine hydroxylase (TH) levels	175
3.5. Statistical analysis	176
4. Results	177
4.1. Test compounds exhibited good DA receptor modulatory effects <i>in vitro</i> assessed by rat superior mesenteric artery	177
4.2. Compound (16) offered protection against 6-OHDA-induced injury in human SH-SY5Y neuroblastoma cell culture through D ₁ agonism	181
4.3. Test compound (16) induced ipsilateral rotations	182
4.4. Test compound (16) exhibited antioxidative effects in 6-OHDA-treated rat brain	183
4.5. Test compound (16) increased DA levels in striatum of 6-OHDA lesioned rats	183
4.6. Test compound (16) diminished cleaved caspase-3 and increased tyrosine hydroxylase (TH) expression in 6-OHDA-induced Parkinson's rat brain	184
5. Discussion	187
6. References	191

<u>Section 5</u>	<u>Page No.</u>
1. Introduction	196
2. Research envisaged	199
3. Materials and methods	201
3.1. Animals	201
3.2. Effect of test compounds on different behavioural rodent models	201
3.2.1. Apomorphine-induced stereotype behaviour	201
3.2.2. Spontaneous locomotor activity	202
3.2.3. 7-OH-DPAT-induced hypothermia	202
3.2.4. Induction of catalepsy	202
3.2.5. Rota rod test for ataxia	202
3.3. Effect of test compounds on DA level in rat brain striatum	203
3.4. Lethality in mice	203
3.5. Statistical analysis	204
4. Results	205
4.1. D ₃ Antagonist activity of test compounds on rat superior mesenteric artery strip	205
4.2. Compounds (8 and 15) attenuated apomorphine-induced stereotype behaviour	205
4.3. Compounds (8 and 15) attenuated spontaneous locomotor activity	205
4.4. Compounds (8 and 15) attenuated 7-OH-DPAT-induced hypothermia	206
4.5. Compounds (8 and 15) did not induce catalepsy at low doses	206
4.6. Compounds (8 and 15) did not induce rota rod ataxia	207

4.7. Compounds (8 and 15) attenuated apomorphine-induced striatal DA level	207
4.8. Compounds (8 and 15) were found safe in acute lethality test	208
5. Discussion	209
6. References	213

<u>Supplementary information</u>	<u>Page No.</u>
SI1. Dose deciding pilot study	216
SI2. <i>In vitro</i> blood-brain barrier permeation assay	217